Gilbertsville, PA. April 2, 2012 – Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies announced the release of 95 antibodies that are involved in signal transduction and cancer research. The antibodies were developed through a partnership with the National Cancer Institute’s Center for Cancer Research. The goal of this collaboration is to combine basic and applied research by working with life science researchers to develop better bioreagents that will facilitate biomedical research.
“Rockland’s antibody technology platform continues to be widely received by the research and biopharma community,” commented James Fendrick, CEO of Rockland Immunochemicals. “We anticipate continued success in our antibody efforts with NCI to discover and develop both novel and existing antibody targets that have broad application in the life science markets.”
All of the antibodies made under the NCI Rockland collaboration are produced in Rockland laboratories located west of Philadelphia, PA. It is anticipated that these reagents will assist in the understanding cell function and disease.
About Rockland Immunochemicals
Rockland Immunochemicals has supported the research, BioPharma and diagnostic industries for over 50 years with the highest quality antibodies and antibody based tools. Rockland is engaged in the development of new technologies for the production of antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA and FLOW cytometry. More information about Rockland Immunochemicals and its products and services can be found at the company’s web site at www.rockland-inc.com
For additional information regarding this announcement, please contact:
Tabitha Patrick
Communications, Rockland Immunochemicals Inc.
Phone: 610.369.1008
Email: patrick@rockland-inc.com
